Furthermore, T cell immunoglobulin and mucin-domain containing-3 (TIM-3) [13], Lymphocyte activation gene-3 (LAG-3) [14], T cell surface protein containing an immunoglobulin variable (IgV) domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM), which is called TIGIT (T cell immunoglobulin and ITIM domain) [15], B and T lymphocyte attenuator (BTLA) [16], V-domain immunoglobulin suppressor of T cell activation (VISTA) [17], and B7 homolog 3 protein (B7-H3) [18] are next-generation of ICPs in the tumor microenvironment (TME). The gene discussed is BTLA; the disease is neoplasm.